Literature DB >> 22207133

Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication.

Sangmu Jun1, Beata Clapp, Dagmara Zlotkowska, Teri Hoyt, Kathryn Holderness, Massimo Maddaloni, David W Pascual.   

Abstract

Sublingual (s.l.) vaccination is an efficient way to induce elevated levels of systemic and mucosal immune responses. To mediate mucosal uptake, ovalbumin (OVA) was genetically fused to adenovirus 2 fiber protein (OVA-Ad2F) to assess whether s.l. immunization was as effective as an alternative route of vaccination. Ad2F-delivered vaccines were efficiently taken up by dendritic cells and migrated mostly to submaxillary gland lymph nodes, which could readily stimulate OVA-specific CD4(+) T cells. OVA-Ad2F + cholera toxin (CT)-immunized mice elicited significantly higher OVA-specific serum IgG, IgA and mucosal IgA antibodies among the tested immunization groups. These were supported by elevated OVA-specific IgG and IgA antibody-forming cells. A mixed T(h)-cell response was induced as evident by the enhanced IL-4, IL-10, IFN-γ and TNF-α-specific cytokine-forming cells. To assess whether this approach can stimulate neutralizing antibodies, immunizations were performed with the protein encumbering the β-trefoil domain of C-terminus heavy chain (Hcβtre) from botulinum neurotoxin A (BoNT/A) as well as when fused to Ad2F. Hcβtre-Ad2F + CT-dosed mice showed the greatest serum IgG, IgA and mucosal IgA titers among the immunization groups. Hcβtre-Ad2F alone also induced elevated antibody production in contrast to Hcβtre alone. Plasma from Hcβtre + CT- and Hcβtre-Ad2F + CT-immunized groups neutralized BoNT/A and protected mice from BoNT/A intoxication. Most importantly, Hcβtre-Ad2F + CT-immunized mice were protected from BoNT/A intoxication relative to Hcβtre + CT-immunized mice, which only showed ∼60% protection. This study shows that s.l. immunization with Ad2F-based vaccines is effective in conferring protective immunity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22207133      PMCID: PMC3270090          DOI: 10.1093/intimm/dxr106

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  64 in total

Review 1.  Bronchus- and nasal-associated lymphoid tissues.

Authors:  John Bienenstock; Mark R McDermott
Journal:  Immunol Rev       Date:  2005-08       Impact factor: 12.988

2.  Sublingual immunization induces broad-based systemic and mucosal immune responses in mice.

Authors:  Nicolas Cuburu; Mi-Na Kweon; Joo-Hye Song; Catherine Hervouet; Carmelo Luci; Jia-Bin Sun; Paul Hofman; Jan Holmgren; Fabienne Anjuère; Cecil Czerkinsky
Journal:  Vaccine       Date:  2007-10-25       Impact factor: 3.641

3.  Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system.

Authors:  Franck Lemiale; Wing-pui Kong; Levent M Akyürek; Xu Ling; Yue Huang; Bimal K Chakrabarti; Michael Eckhaus; Gary J Nabel
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

4.  Oral tolerance revisited: prior oral tolerization abrogates cholera toxin-induced mucosal IgA responses.

Authors:  H Kato; K Fujihashi; R Kato; Y Yuki; J R McGhee
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

5.  Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin.

Authors:  David J M Lewis; Zhiming Huo; Susan Barnett; Ingrid Kromann; Rafaela Giemza; Eva Galiza; Maria Woodrow; Birgit Thierry-Carstensen; Peter Andersen; Deborah Novicki; Giuseppe Del Giudice; Rino Rappuoli
Journal:  PLoS One       Date:  2009-09-16       Impact factor: 3.240

6.  Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine.

Authors:  Mingtao Zeng; Qingfu Xu; Md Elias; Michael E Pichichero; Lance L Simpson; Leonard A Smith
Journal:  Vaccine       Date:  2007-09-05       Impact factor: 3.641

7.  Subunit vaccine against the seven serotypes of botulism.

Authors:  Michael R Baldwin; William H Tepp; Amanda Przedpelski; Christina L Pier; Marite Bradshaw; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

8.  Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis.

Authors:  Alain Didier; Hans-Jörgen Malling; Margitta Worm; Friedrich Horak; Siegfried Jäger; Armelle Montagut; Claude André; Olivier de Beaumont; Michel Melac
Journal:  J Allergy Clin Immunol       Date:  2007-11-01       Impact factor: 10.793

9.  Novel vaccination protocol with two live mucosal vectors elicits strong cell-mediated immunity in the vagina and protects against vaginal virus challenge.

Authors:  Zhongxia Li; Manxin Zhang; Chenghui Zhou; Xinyan Zhao; Norifumi Iijima; Fred R Frankel
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

Review 10.  Strategies to design inhibitors of Clostridium botulinum neurotoxins.

Authors:  S Cai; B R Singh
Journal:  Infect Disord Drug Targets       Date:  2007-03
View more
  5 in total

1.  Vaccine delivery to the oral cavity using coated microneedles induces systemic and mucosal immunity.

Authors:  Yunzhe Ma; Wenqian Tao; Shelly J Krebs; William F Sutton; Nancy L Haigwood; Harvinder S Gill
Journal:  Pharm Res       Date:  2014-03-13       Impact factor: 4.200

2.  Sublingual immunization of trivalent human papillomavirus DNA vaccine in baculovirus nanovector for protection against vaginal challenge.

Authors:  Hee-Jung Lee; Hansam Cho; Mi-Gyeong Kim; Yoon-Ki Heo; Yeondong Cho; Yong-Dae Gwon; Ki Hoon Park; Hyerim Jin; Jinyoung Kim; Yu-Kyoung Oh; Young Bong Kim
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

3.  Intratracheal inoculation of AHc vaccine induces protection against aerosolized botulinum neurotoxin A challenge in mice.

Authors:  Changjiao Gan; Wenbo Luo; Yunzhou Yu; Zhouguang Jiao; Sha Li; Duo Su; Junxia Feng; Xiaodong Zhao; Yefeng Qiu; Lingfei Hu; Dongsheng Zhou; Xiaolu Xiong; Jinglin Wang; Huiying Yang
Journal:  NPJ Vaccines       Date:  2021-06-22       Impact factor: 7.344

Review 4.  Antibodies and Vaccines against Botulinum Toxins: Available Measures and Novel Approaches.

Authors:  Christine Rasetti-Escargueil; Michel R Popoff
Journal:  Toxins (Basel)       Date:  2019-09-12       Impact factor: 4.546

Review 5.  Buccal and sublingual vaccine delivery.

Authors:  Heleen Kraan; Hilde Vrieling; Cecil Czerkinsky; Wim Jiskoot; Gideon Kersten; Jean-Pierre Amorij
Journal:  J Control Release       Date:  2014-06-06       Impact factor: 9.776

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.